Pharma: Other News To Note
Wednesday, August 22, 2012
GE Healthcare, of Princeton, N.J., said the label for contrast agent Optison (perflutren protein-Type A microspheres injectable suspension, USP) was updated to include warnings about serious cardiopulmonary reactions.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.